Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells
- PMID: 17312122
- DOI: 10.4049/jimmunol.178.5.2787
Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells
Abstract
Glycoprotein tumor Ag MUC1 is overexpressed on the majority of epithelial adenocarcinomas. CTLs that recognize MUC1 and can kill tumor cells that express this molecule have been found in cancer patients, yet they are present in low frequency and unable to eradicate MUC1(+) tumors. Patients also make anti-MUC1 Abs but predominantly of the IgM isotype reflecting the lack of effective MUC1-specific Th responses. Mice transgenic for the human MUC1 gene (MUC1-Tg) are similarly hyporesponsive to MUC1. We used a vaccine consisting of dendritic cells loaded with a long synthetic MUC1 peptide to investigate the fate and function of MUC1-specific CD4(+) Th elicited in wild-type (WT) or MUC1-Tg mice or adoptively transferred from vaccinated WT mice. We show that hyporesponsiveness of MUC1-Tg mice to this vaccine is a result of insufficient expansion of Th cells, while at the same time their regulatory T cells are efficiently expanded to the same extent as in WT mice and exert a profound suppression on MUC1-specific B and T cell responses in vivo. Adoptive transfer of WT Th cells relieved this suppression and enhanced T and B cell responses to subsequent MUC1 immunization. Our data suggest that the balance between Th and regulatory T cells is a critical parameter that could be modulated to improve the response to cancer vaccines.
Similar articles
-
Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.J Immunol. 2001 Jun 1;166(11):6555-63. doi: 10.4049/jimmunol.166.11.6555. J Immunol. 2001. PMID: 11359807
-
Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA.J Immunol. 2000 Nov 15;165(10):5713-9. doi: 10.4049/jimmunol.165.10.5713. J Immunol. 2000. PMID: 11067929
-
A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice.Vaccine. 2006 Apr 12;24(16):3340-52. doi: 10.1016/j.vaccine.2006.01.014. Epub 2006 Jan 19. Vaccine. 2006. PMID: 16472547
-
Tecemotide: an antigen-specific cancer immunotherapy.Hum Vaccin Immunother. 2014;10(11):3383-93. doi: 10.4161/hv.29836. Hum Vaccin Immunother. 2014. PMID: 25483673 Free PMC article. Review.
-
Making the most of mucin: a novel target for tumor immunotherapy.Cancer Immunol Immunother. 1996 Nov;43(3):142-51. doi: 10.1007/s002620050315. Cancer Immunol Immunother. 1996. PMID: 9001567 Review.
Cited by
-
Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles.Cancer Immunol Immunother. 2010 Nov;59(11):1685-96. doi: 10.1007/s00262-010-0895-0. Epub 2010 Jul 21. Cancer Immunol Immunother. 2010. PMID: 20652244 Free PMC article.
-
Antitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model.J Transl Med. 2013 Mar 13;11:64. doi: 10.1186/1479-5876-11-64. J Transl Med. 2013. PMID: 23496860 Free PMC article.
-
Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1.Blood. 2008 Oct 1;112(7):2817-25. doi: 10.1182/blood-2008-05-157396. Epub 2008 Jul 31. Blood. 2008. PMID: 18669871 Free PMC article.
-
Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses.Cancer Res. 2010 Jul 15;70(14):5788-96. doi: 10.1158/0008-5472.CAN-09-4519. Epub 2010 Jun 29. Cancer Res. 2010. PMID: 20587526 Free PMC article.
-
Efficacy of intracellular immune checkpoint-silenced DC vaccine.JCI Insight. 2018 Feb 8;3(3):e98368. doi: 10.1172/jci.insight.98368. eCollection 2018 Feb 8. JCI Insight. 2018. PMID: 29415891 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous